Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HRTX Heron Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: HRTX
Price (delayed)
$2.04
Market cap
$311.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.05
Enterprise value
$469.22M
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron
Highlights
Heron Therapeutics's EPS has surged by 92% YoY and by 44% QoQ
Heron Therapeutics's net income has soared by 90% YoY and by 43% from the previous quarter
The quick ratio has contracted by 20% YoY and by 3.3% from the previous quarter
Key stats
What are the main financial stats of HRTX
Market
Valuations
Earnings
Shares outstanding
152.56M
Market cap
$311.23M
Enterprise value
$469.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
Revenue
$148.52M
Gross profit
$109.86M
Operating income
-$3.58M
Net income
-$7.79M
EBIT
-$5.3M
EBITDA
-$2.95M
Free cash flow
-$23.63M
Per share
Balance sheet
Liquidity
EPS
-$0.05
EPS diluted
-$0.06
Free cash flow per share
-$0.15
Book value per share
-$0.19
Revenue per share
$0.97
TBVPS
$1.54
Total assets
$235.75M
Total liabilities
$264.21M
Debt
$177.26M
Equity
-$28.45M
Working capital
$124.28M
Debt to equity
-6.23
Current ratio
2.4
Quick ratio
1.46
Net debt/EBITDA
-53.57
Margins
Efficiency
Dividend
EBITDA margin
-2%
Gross margin
74%
Net margin
-5.2%
Operating margin
-2.4%
Return on assets
-3.4%
Return on equity
N/A
Return on invested capital
-1.8%
Return on capital employed
-3.6%
Return on sales
-3.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRTX stock price
How has the Heron Therapeutics stock price performed over time
Intraday
2%
1 week
11.48%
1 month
-11.69%
1 year
-43.33%
YTD
33.33%
QTD
-7.27%
Financial performance
How have Heron Therapeutics's revenue and profit performed over time
Revenue
$148.52M
Gross profit
$109.86M
Operating income
-$3.58M
Net income
-$7.79M
Gross margin
74%
Net margin
-5.2%
HRTX's operating margin has surged by 96% year-on-year and by 70% since the previous quarter
The operating income has surged by 96% year-on-year and by 69% since the previous quarter
The net margin has soared by 92% year-on-year and by 45% since the previous quarter
Heron Therapeutics's net income has soared by 90% YoY and by 43% from the previous quarter
Price vs fundamentals
How does HRTX's price correlate with its fundamentals
Growth
What is Heron Therapeutics's growth rate over time
Valuation
What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
Heron Therapeutics's EPS has surged by 92% YoY and by 44% QoQ
The equity is up by 16% year-on-year and by 15% since the previous quarter
HRTX's price to sales (P/S) is 70% less than its 5-year quarterly average of 7.0 and 16% less than its last 4 quarters average of 2.5
HRTX's revenue is up by 12% year-on-year and by 2.9% since the previous quarter
Efficiency
How efficient is Heron Therapeutics business performance
The ROIC has soared by 94% YoY and by 53% from the previous quarter
Heron Therapeutics's return on sales has surged by 94% YoY and by 53% QoQ
HRTX's ROA has soared by 91% YoY and by 44% QoQ
Dividends
What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRTX.
Financial health
How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 11% lower than its total liabilities
The quick ratio has contracted by 20% YoY and by 3.3% from the previous quarter
Heron Therapeutics's total assets has increased by 8% YoY
The debt to equity has declined by 18% since the previous quarter and by 17% year-on-year
The equity is up by 16% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.